Elranatamab

No information is available on the use of elranatamab during breastfeeding. Because elranatamab is a large protein molecule with a molecular weight of about 148,500 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] The manufacturer recommends that breastfeeding be discontinued during therapy and 4 months after the last dose.